Evidence map›Paper›PMID 42775253›Full record

ArticleFrontiers in pharmacology2026

Hesperidin reduces genomic instability in glioblastoma cells and is associated with reduced HNRNPA2B1/m

Viktoriia Sazonova, Pavel Zun, Ilia Tonkji, Sergey Onikienko, Tatyana Erofeeva, Vadim Basharin, Nadezhda Zhigalova, Alexandra Ilyushkina, Ekaterina Skorb, Alexey Ruzov and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Viktoriia SazonovaInfochemistry Scientific Center, ITMO University, Saint Petersburg, Russia.
Pavel ZunInfochemistry Scientific Center, ITMO University, Saint Petersburg, Russia.
Ilia TonkjiInfochemistry Scientific Center, ITMO University, Saint Petersburg, Russia.
Sergey OnikienkoPersonalized Biomedical Technologies Sector of the Saint Petersburg Research Center of the Russian Academy of Sciences, Saint Petersburg, Russia.
Tatyana ErofeevaDepartment Toxicology of Medical Academy, Saint Petersburg, Russia.
Vadim BasharinDepartment Toxicology of Medical Academy, Saint Petersburg, Russia.
Nadezhda ZhigalovaInstitute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia.
Alexandra IlyushkinaInstitute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia.
Ekaterina SkorbInfochemistry Scientific Center, ITMO University, Saint Petersburg, Russia.
Alexey RuzovPersonalized Biomedical Technologies Sector of the Saint Petersburg Research Center of the Russian Academy of Sciences, Saint Petersburg, Russia.
Sergey ShityakovInfochemistry Scientific Center, ITMO University, Saint Petersburg, Russia.
Viacheslav KravtsovInfochemistry Scientific Center, ITMO University, Saint Petersburg, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genomic instability contributes to tumor progression and limits the effectiveness of anticancer therapy. In this study, we investigated whether the citrus flavonoid hesperidin influences cytogenetic damage and epitranscriptomic markers in tumor cells exposed to ionizing radiation or maintained under long-term culture conditions. In human glioblastoma cell lines U87MG and LN229, hesperidin reduced radiation-induced micronucleus formation and decreased the spontaneous micronucleus frequency during prolonged passaging with repeated supplementation. Immunocytochemical analysis demonstrated that long-term hesperidin treatment was accompanied by reduced HNRNPA2B1 protein expression and lower global m

Indexed as

epitranscriptomicsgenomic instabilityglioblastomahesperidinHNRNPA2B1ionizing radiationM6A RNA methylationmicronuclei

Identifiers

PMID42775253
PMCPMC13595929

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.